The American Pharmacists Association (APhA) has selected seven recipients of its 2025 Immunization Champion Awards, recognizing individuals and organizations who have made extraordinary contributions ...

Persistent levels of spike protein from COVID-19 vaccines could be associated with a range of chronic symptoms like excessive ...

CoV-2, has been discovered in China and is “strikingly similar to the pandemic virus” and feared to be powerful ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Harvard Business School Online launches a six-month program to help professionals understand digital transformation, leverage ...

DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

Moderna Inc. MRNA edged up 0.58%, while Pfizer Inc. PFE gained 2.95% amid heightened focus on potential bird flu preparedness. CDC official John Nkengasong‘s Sunday memo, viewed by The ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

The Moderna and Pfizer agreements include options for a total of 600 million doses, 300 million apiece, but these can only be exercised with additional funding from Congress, according to HHS.

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax, following in the footsteps of Pfizer/BioNTech, which filed their Comirnaty shot ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.